Hepatitis E Virus Seroprevalence in Austrian Adults: A Nationwide Cross-Sectional Study among Civilians and Military Professionals

Heimo Lagler¹, Wolfgang Poeppl¹,², Heidi Winkler¹, Harald Herkner³, Angelus Faas⁴, Gerhard Mooseder², Heinz Burgmann¹*

¹Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria, ²Department of Dermatology and Tropical Medicine, Military Hospital Vienna, Vienna, Austria, ³Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria, ⁴Institute for Medical Support, Military Hospital Vienna, Vienna, Austria

Abstract

Background: Hepatitis E Virus (HEV) infection is globally increasing. The present study was performed to investigate the HEV seroprevalence, exposure risks as well as occupational risks for military personnel in Austria, a Central European country.

Methods and Findings: A nationwide cross-sectional seroprevalence study was performed in 997 healthy Austrian adults, professional soldiers and civilians. Routine laboratory and HEV specific antibodies were determined. In addition, epidemiological information on possible risk factors for exposure to HEV was obtained. The overall seropositivity for HEV antibodies was 14.3% and significantly increased with age. Seroprevalence was significantly higher among individuals with previous military employment abroad (21.4% vs. 9.9%) and among professional soldiers aged 30–39 years (20.2% vs. 7.3%). No association was found for private travel, occupational or private animal contact or regular outdoor activities. Individuals who tested positive for antibodies against HEV had significantly higher laboratory values regarding liver enzymes, lipid levels and blood fasting glucose.

Conclusions: Exposure to HEV is common in Austria. Military employment abroad could be a potential risk factor for HEV infection. Further studies are required to investigate the significance of pathological laboratory results found among asymptomatic individuals previously exposed to HEV.

Introduction

Hepatitis E virus (HEV) is a non-enveloped, single-stranded RNA virus belonging to the genus Hepatitis in the Hepeviridae family. HEV has initially been identified as an enterically transmitted “epidemic, non-A, non-B hepatitis” in the early 1980s in developing countries, while the viral genome was characterized one decade later [1,2]. There is, however, evidence that worldwide human outbreaks of icteric illness due to HEV infections had already occurred more than 200 years ago, particularly in Europe [3]. Until recently, HEV infection was considered to be a travel-associated disease widely endemic in developing countries. In the last decade, however, HEV infection has increasingly been recognized as an emerging disease in both developing and industrialized countries.

HEV is currently classified into four major genotypes, which all belong to one serotype. These genotypes differ in terms of epidemiological distribution, clinical presentation and host species. Genotype 1 and 2 are endemic in developing and industrialized countries, infect only humans, while no animal reservoir has been identified. Infection usually occurs by fecal-oral transmission and may result in hepatitis with fever, jaundice and nausea. In developed countries, these two genotypes are known as travel-associated HEV infection. By contrast, genotype 3 is endemic mainly in Europe and Northern America and genotype 4 in Asia [4]. Apart from human infection, genotypes 3 or 4 have also been isolated in several mammalian species, such as domestic pigs, wild boar, deer, and rodents, but also marine animals [5]. Infection in humans may result from consumption of raw or not well-cooked nutritional constituents or direct contact with infected animals [6,7]. In addition, HEV has been detected in soil, river water, waste, as well as pig slurry, and may therefore be considered a zoonotic disease transmitted through exposure to contaminated environment [8–11]. Recently, additional HEV genotypes have been identified in farmed rabbits, rats and birds [12]. The relevance of these findings for human infection is yet unclear. Infection with HEV genotype 3 or 4 is usually asymptomatic or mild and patients will probably escape medical attention [13]. However, acute hepatitis may occur, and severe disease with rapid progression and liver-failure has been
reported in pregnant women, immuno-compromised patients as well as patients with chronic underlying liver diseases [4].

Globally, the impact of HEV infections on public health has apparently been underestimated. In Europe, seroprevalences differ considerably, ranging from 0.26% in central Greece to 52.5% in South-Western France, but little information is available on exposure risks or potential high-risk groups [14,15].

Since its discovery, several outbreaks of HEV infection have been reported among military personnel, particularly during or following activities in endemic areas [4,16–19]. Thus, military personnel are considered an occupational high risk group for HEV infection. However, this assumption is based on case series and outbreak reports only, as no studies have been performed comparing exposure to HEV between professional soldiers and civilians.

Thus, the present study was initiated in order to investigate the seroprevalence of specific antibodies against HEV in (apparently) healthy adult individuals in Austria and to identify possible exposure factors for military personnel as well as civilians.

Materials and Methods

Subjects and study design

We have performed a nationwide cross-sectional study in healthy Austrian adults volunteering for military employments abroad. Before potential selection, all Austrian applicants (civilians as well as professional soldiers), have to undergo a standardized medical examination including routine laboratory investigations at the Military Hospital Vienna. The routinely performed laboratory investigations include erythrocyte sedimentation rate, total blood counts, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), gamma-glutamyl transferase (gGT), total bilirubin, cholesterol including low density lipoprotein (LDL), high-density lipoprotein (HDL), uric acid, serum creatinine and fasting glucose.

The study was approved by the Institutional Review Board of the Austrian armed forces and written informed consent was obtained from each participant before inclusion in the study.

For study purposes, an additional serum sample was obtained from each participant and stored at −20°C until qualitative testing for HEV specific IgG antibodies using an enzyme linked immunosorbent assay (ELISA, Fortress Diagnostics Limited, Antrim, United Kingdom) performed according to the manufacturer’s instructions. According to the package insert, this ELISA is especially suitable for HEV prevalence studies amongst larger populations, as 86% of 50 samples were still positive on re-testing ten years after confirmed HEV infection. This kit uses one long recombinant protein (PE2) of a Chinese strain belonging to genotype 1, and the sensitivity of this ELISA kit was 95% in samples from patients with PCR-confirmed HEV genotype 3 infection [20]. The ELISA Kit produced by Fortress, as used in this study, has given identical results in direct comparison to another assay produced by Wantai (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd, China) [21]. The specificity for the ELISA produced by WANTAI was evaluated in 9000 persons and was shown to be 98.6% according to the package insert.

All samples were tested in duplicate. Each sample with an individual absorbance (OD) of a specimen/cut off (CO) value ≥0.9 was retested in duplicate and was considered positive only if the OD/CO value of both replicates was ≥1.0. The positive control was part of the kit provided by the manufacturer.

In addition, all participants were asked to complete an epidemiological questionnaire on demographic characteristics and potential risks of exposure (e.g. domestic and occupational animal contact, outdoor activities, holiday destinations abroad within the previous six months, previous military missions abroad).

Statistics

In the absence of reliable estimates on HEV prevalence, we did not perform a formal sample size calculation. Instead, we used a convenient sample size of approximately 1000 individuals based on the available resources. With this sample, one can expect a 95% confidence interval (CI) from 8 to 12% assuming a prevalence of 10%. Data are presented as mean ± standard deviation (SD); categorical data are presented as absolute and relative frequencies. The Mann–Whitney U test, Chi-squared and Fisher’s exact test were used as appropriate for hypothesis testing to describe differences between negative and positive individuals. Prevalence of anti-HEV antibodies was described as relative frequency with exact 95% CIs. Odds ratios (OR) with exact 95% CIs were calculated using logistic regression models for identification of risk factors for seropositivity to HEV. MS Excel 2011 and Stata 11 for Mac (College Station, Tx) were used for data management and analysis. A two-sided P-value of <0.05 was considered statistically significant.

Results

In total, 997 healthy Austrians aged between 18–59 years participated in the study from April to September 2009, with 980 (98.3%) being male and 17 (0.7%) female. The mean age of all individuals was 29±9.3 years; 407 (40.8%) participants were professional soldiers and 590 (59.2%) were civilians.

Overall, 143 sera (14.3%, 95% CI 11.5%–15.8%) showed a positive reaction for IgG antibodies against HEV indicating previous exposure. The detected OD/CO rates of the IgG HEV ELISA showed a clear bimodal distribution. In particular, the median OD/CO value was 6.1 (25% percentile 2.1, 75% percentile 14.6) in the 143 samples tested positive and 0.2 (25% percentile 0.1, 75% percentile 0.5) in the 860 negative samples.

The mean age of individuals who tested positive for the presence of HEV antibodies was 35.1±11.3 years versus 27.9±8.4 years for those with negative screening results (p<0.001). We found a significant trend for increasing seropositivity with increasing age (p for trend <0.001). Among individuals aged up to 19 years, the seroprevalence was 8.1% and increased to a seroprevalence rate of 57.5% (OR 15.46, 95% CI 5.71–41.82, p<0.001) among individuals aged 50–60 years (Table 1).

Concerning differences between the various provinces of Austria, seropositivity was lowest in the Western parts of Austria with seroprevalences of 3.3% in Vorarlberg, and increased to the East with a seroprevalence of 20.3% in Burgenland. These differences, however, were not statistically significant (p = 0.35; Table 1).

Univariate associations between potential risk factors for positive serology results are presented in Table 2. Specifically, there was no statistically significant difference in HEV seroprevalence between occupational animal contact and ownership of companion animals. No association was found for seropositivity against HEV virus and regular outdoor-activities.

Regarding military activities, the proportion of seropositive samples was significantly higher among professional soldiers aged 30–39 years when compared to civilians, but significantly lower among professional soldiers aged 40–49 years (p for interaction 0.0049; Table 2). Overall, 378 (37.9%) individuals had had at least one military employment abroad, and the seroprevalence was significantly higher in this cohort (21.4% vs. 9.9%, p<0.001). A positive correlation was also found with the number of previous
military employments abroad (OR 1.26, 95% CI 1.14–1.39, 
p < 0.001).

Concerning private travel abroad, 216 (21.7%) individuals reported at least one private travel abroad in the last six months. While no significant association was found (17.6% vs. 13.3%), the rate of seropositivity increased significantly with the number of private travel activities (OR 1.32, 95% CI 1.02–1.71, p = 0.04). Combining military employments abroad and private travel activities, a total of 486 (48.7%) individuals reported a history of having travelled abroad, and the seroprevalence was significantly higher in this group versus the cohort of “non-travellers” (19.3% vs. 9.4%; Table 2).

In terms of routine laboratory results, individuals who tested positive for antibodies against HEV had significantly higher values regarding liver enzymes, blood cholesterol and blood fasting glucose. The results in detail were as follows (including normal range): ALAT 32±18 U/l vs. 29±16 U/l, p = 0.01 (female < 35 U/l, male < 50 U/l); gGT 30±23 U/l vs. 24±16 U/l, p < 0.001 (< 60 U/l); cholesterol 202±42 mg/dl vs. 188±39 mg/dl, p < 0.001 (< 200 mg/dl); LDL cholesterol 134±36 mg/dl vs. 121±35 mg/dl, p < 0.001 (< 160 mg/dl); fasting glucose 98±9 mg/dl vs. 96±8 mg/dl, p = 0.01 (74–109 mg/dl).

Discussion

In this first large Austrian study, the overall seroprevalence of 14.3% appears comparable to data obtained in healthy blood donors from other developed countries and identical HEV IgG ELISA. A seroprevalence of 21.8% was reported in 2009 for South-Western Switzerland, while the seroprevalences reported in South-Western England and the USA were 16% and 18.8%, respectively [20,22,23].

Of interest are older data reported for the year 1995, when a seroprevalence of only 2.3% was found among 1094 adult individuals in Vienna [24]. However, it is known that estimates of HEV seroprevalence are highly dependent on assay sensitivity and that assays with improved sensitivity result in higher seroprevalence rates [15,20,21,23]. As the assay used in our present study is different from the one applied in the study from Vienna in 1995, one cannot interpret the difference as an increase in prevalence due to the higher sensitivity of our HEV IgG ELISA [20,21].

In terms of geographical distribution within Austria, the lowest rate of 5.3% was found in individuals from the Western federal province Vorarlberg. In general, the present data suggested an increasing seroprevalence from Western to Eastern Austria. Unlike other viral hepatitis infections occurring in humans, HEV infection may also be considered a zoonosis and especially pigs are considered important reservoir animals. In Austria, the HEV genotype 3 has recently been detected in pigs [25]. Thus, a possible explanation for the geographic differences might be the distribution of industrialized pig farms in Austria, as the federal districts in the middle and Eastern parts of Austria where high seroprevalences were found (Burgenland, Lower Austria, Upper Austria and Styria) correspond to the regions of industrialized pig farming.

Interestingly, the data obtained from the present study revealed a distinct and significant increase of HEV-antibodies with age, with the seroprevalence being > 55% in individuals aged 50–59 years. The nationwide seroprevalences in this age group is thus comparable to a hyperendemic area in South-west France [15]. Age dependent HEV seroprevalences, however, have also been reported in previous studies independent of the HEV ELISA assays used, although to our knowledge not all to this extent [18,26,27]. In Germany, the seroprevalence increased from approximately 6% among persons aged 20–29 to approximately 20% among persons 50–59 years of age [28].

Concerning occupational risk, HEV virus has been recognized as a potential threat to military forces since its discovery [4]. However, only a few studies have investigated the risk of HEV exposure for military personnel so far. From Nepal and Pakistan, seroprevalence rates of 30% among military personnel have been reported [16,17]. Among 1500 US military service members deployed to Afghanistan, a low seroconversion rate of only 0.13% has recently been reported [18]. Among soldiers from Thailand being on active duty in the HEV-endemic areas in East Timor, Afghanistan, Burundi, and Iraq, the seroconversion rates were 1.9%, 4.6%, 4.6% and 3.9%, respectively [19]. Data directly comparing HEV exposure among soldiers and civilians, however, are not available. Among the study population used in our present series, a significant association for seropositivity and professional soldiers was found in individuals aged 30–39 years. Additionally, the present data indicate that previous military missions abroad (Table 2), as well as the number of previous military employments and travel-associated disease, private travel abroad in general was not associated with a higher risk of HEV exposure. However, seropositivity was significantly higher among frequent travellers with more than one trip abroad within the last six months before inclusion in the study.

Additional potential risk factors for HEV were evaluated in the present study, but no association between HEV-seropositivity and occupational animal contact, companion animals or outdoor

| Table 1. Age and geographical distribution of 143 individuals seropositive to Hepatitis E virus among 997 healthy adults. |
| Positives/Total (%) | Odds ratio (95% CI) | P value |
| Age groups | |
| 18–19 | 7/87 (8.1%) | 1 (reference) | – |
| 20–29 | 51/544 (9.4%) | 1.18 (0.52 to 2.70) | 0.69 |
| 30–39 | 28/209 (13.4%) | 1.78 (0.74 to 4.21) | 0.20 |
| 40–49 | 33/117 (28.2%) | 4.49 (1.88 to 10.73) | 0.001 |
| 50–60 | 23/40 (57.5%) | 15.46 (5.71 to 41.82) | < 0.001 |
| Federal provinces of Austria | |
| Vienna | 16/128 (12.5%) | 1 (reference) | – |
| Lower Austria | 41/223 (18.4%) | 1.58 (0.85 to 2.94) | 0.15 |
| Upper Austria | 19/148 (12.8%) | 1.03 (0.51 to 2.10) | 0.93 |
| Salzburg | 7/63 (11.1%) | 0.88 (0.34 to 2.25) | 0.78 |
| Tyrol | 6/55 (10.9%) | 0.86 (0.32 to 2.32) | 0.76 |
| Vorarlberg | 1/19 (5.3%) | 0.39 (0.05 to 3.11) | 0.37 |
| Burgenland | 12/59 (20.3%) | 1.79 (0.79 to 4.06) | 0.17 |
| Styria | 19/167 (11.4%) | 0.90 (0.44 to 1.83) | 0.77 |
| Carinthia | 20/133 (15.0%) | 1.24 (0.61 to 2.51) | 0.55 |

Abbreviations: CI, confidence interval. doi:10.1371/journal.pone.0087669.t001

Concerning private travel abroad, 216 (21.7%) individuals reported at least one private travel abroad in the last six months. While no significant association was found (17.6% vs. 13.3%), the rate of seropositivity increased significantly with the number of private travel activities (OR 1.32, 95% CI 1.02–1.71, p = 0.04). Combining military employments abroad and private travel activities, a total of 486 (48.7%) individuals reported a history of having travelled abroad, and the seroprevalence was significantly higher in this group versus the cohort of “non-travellers” (19.3% vs. 9.4%; Table 2).

In terms of routine laboratory results, individuals who tested positive for antibodies against HEV had significantly higher values regarding liver enzymes, blood cholesterol and blood fasting glucose. The results in detail were as follows (including normal range): ALAT 32±18 U/l vs. 29±16 U/l, p = 0.01 (female < 35 U/l, male < 50 U/l); gGT 30±23 U/l vs. 24±16 U/l, p < 0.001 (< 60 U/l); cholesterol 202±42 mg/dl vs. 188±39 mg/dl, p < 0.001 (< 200 mg/dl); LDL cholesterol 134±36 mg/dl vs. 121±35 mg/dl, p < 0.001 (< 160 mg/dl); fasting glucose 98±9 mg/dl vs. 96±8 mg/dl, p = 0.01 (74–109 mg/dl).
Table 2. Risk factors for positive hepatitis E screening results.

| Risk factors                              | Level | Positives/Total (%) | Odds ratio (95% CI) | P value |
|-------------------------------------------|-------|---------------------|---------------------|---------|
| Male                                      | yes   | 139/980 (14.2%)     | 0.77 (0.22 to 2.72) | 0.72    |
|                                           | no    | 3/17 (17.7%)        |                     |         |
| Outdoor activities                        | yes   | 113/795 (14.2%)     | 0.99 (0.64 to 1.54) | 0.96    |
|                                           | no    | 29/202 (14.4%)      |                     |         |
| Professional soldier by age               | 18–19 | yes 4/35 (11.4%)    | 2.11 (0.44 to 10.01) | 0.35    |
|                                           | no    | 3/52 (5.8%)         |                     |         |
|                                           | 20–29 | yes 19/190 (10.0%)  | 1.12 (0.62 to 2.03) | 0.71    |
|                                           | no    | 32/354 (9.0%)       |                     |         |
|                                           | 30–39 | yes 20/99 (20.2%)   | 3.23 (1.35 to 7.71) | 0.008   |
|                                           | no    | 8/110 (7.3%)        |                     |         |
|                                           | 40–49 | yes 10/57 (17.5%)   | 0.34 (0.15 to 0.81) | 0.01    |
|                                           | no    | 23/60 (38.3%)       |                     |         |
|                                           | 50–60 | yes 16/26 (61.5%)   | 1.60 (0.43 to 5.94) | 0.48    |
|                                           | no    | 7/7 (50.0%)         |                     |         |
| Previous mission abroad                   | yes   | 81/378 (21.4%)      | 2.49 (1.74 to 3.58) | <0.001  |
|                                           | no    | 61/619 (9.9%)       |                     |         |
| Central or Northern Europe                | yes   | 0/3 (0%)            | n.a.                | 1       |
|                                           | no    | 81/375 (21.6%)      |                     |         |
| Southern Europe                           | yes   | 57/285 (20.0%)      | 0.72 (0.42 to 1.24) | 0.24    |
|                                           | no    | 24/93 (25.8%)       |                     |         |
| Middle East                               | yes   | 27/129 (20.9%)      | 0.96 (0.57 to 1.61) | 0.87    |
|                                           | no    | 54/249 (21.7%)      |                     |         |
| Africa                                    | yes   | 4/14 (29.0%)        | 1.49 (0.46 to 4.88) | 0.51    |
|                                           | no    | 77/364 (21.2%)      |                     |         |
| Asia                                      | yes   | 7/18 (38.9%)        | 2.46 (0.92 to 6.56) | 0.72    |
|                                           | no    | 74/360 (20.6%)      |                     |         |
| Private travel abroad                     | yes   | 38/216 (17.6%)      | 1.39 (0.93 to 2.08) | 0.12    |
|                                           | no    | 104/781 (13.3%)     |                     |         |
| Occupational animal contact               | yes   | 8/62 (12.9%)        | 0.89 (0.41 to 1.90) |         |
|                                           | no    | 134/935 (14.3%)     |                     |         |
| Meat processing                           | yes   | 0/4 (0%)            | n.a.                | 1       |
|                                           | no    | 142/993 (14.3%)     |                     |         |
| Canine unit                               | yes   | 0/4 (0%)            | n.a.                | 1       |
|                                           | no    | 142/993 (14.3%)     |                     |         |
| Hunter                                    | yes   | 1/3 (33.3%)         | 3.03 (0.28 to 33.58) | 0.37    |
|                                           | no    | 141/994 (14.2%)     |                     |         |
| Kitchen                                   | yes   | 1/14 (7.1%)         | 0.46 (0.06 to 3.54) | 0.46    |
|                                           | no    | 141/983 (14.3%)     |                     |         |
| Agriculture                               | yes   | 5/23 (21.7%)        | 1.70 (0.62 to 4.65) | 0.31    |
|                                           | no    | 137/974 (14.1%)     |                     |         |
| Horses/rider                              | yes   | 1/5 (20%)           | 1.51 (0.17 to 13.60) | 0.54    |
|                                           | no    | 141/992 (14.2%)     |                     |         |
| Companion animal                          | yes   | 60/471 (12.7%)      | 0.79 (0.55 to 1.13) | 0.21    |
|                                           | no    | 82/526 (15.6%)      |                     |         |
| Amphibians                                | yes   | 0/1 (0%)            | n.a.                | 1       |
|                                           | no    | 142/996 (14.3%)     |                     |         |
| Fish-keeping                              | yes   | 1/7 (14.3%)         | 1.00 (0.12 to 8.40) | 0.1     |
|                                           | no    | 141/990 (14.3%)     |                     |         |
activities could be found. One of the potential caveats, however, is the fact that the cohorts presenting with these specific risk factors are too small to allow for definitive conclusions.

In general, HEV infection is considered an emerging disease with an increasing prevalence worldwide. Fortunately, the great majority of infections among healthy individuals are mild and self-limiting and are apparently not associated with prolonged liver dysfunction. Of interest is the fact that significantly higher levels of liver enzymes, blood fatty acids and fasting glucose were detected among healthy individuals seropositive to HEV in the present study, even though they were still within the physiological range. This finding merits further investigations on the long-term medical relevance of exposure to HEV in healthy adults.

A possible limitation of the study is the fact that the population studied almost exclusively comprised of healthy male adults. However, outbreak reports as well as epidemiological studies have shown no significant difference concerning sex and exposure to HEV [28,30,31]. Thus, the male predominance in our study population does not appear to constitute a major confounding factor. Seroprevalences, however, are dependent on the sensitivity and specificity of the assay used in various studies. As a consequence, a comparison of seroprevalence studies performed with different HEV assays is of limited significance. In addition, further confirmatory assays for HEV IgGs are currently not available.

In conclusion, our data demonstrate that exposure to HEV is a common phenomenon in the Austrian population studied. Military employments abroad and frequent travel activities could be potential risk factors. Further studies are warranted to investigate the significance of differences found concerning laboratory results among asymptomatic individuals previously exposed to HEV.

Acknowledgments

The authors thank Warrant Sergeant Guenther Schreiner, Institute for Medical Support, Military Hospital Vienna, and ADir Bernhard Wardein, Central Laboratory, Military Hospital Vienna, for their kind cooperation, valuable suggestions and support.

Author Contributions
Conceived and designed the experiments: HL WP AF GM HB. Performed the experiments: HL WP HW AF GH. Analyzed the data: HH HB. Contributed reagents/materials/analysis tools: HL WP HH AF GH HB. Wrote the paper: HL WP HB.

References
1. Wong DC, Purcell RH, Sreenivasan MA, Prasad SR, Pawri KM (1980) Epidemic and endemic hepatitis in India: evidence for a non-A, non-B hepatitis virus aetiology. Lancet 2: 876-879.
2. Reyes GR, Purdy MA, Kim JP, Luk KC, Young LM, et al. (1990) Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science 247: 1333-1339.
3. Teo CG (2012) Fatal outbreaks of jaundice in pregnancy and the epidemic history of hepatitis E. Epidemiol Infect 140: 767-787.
4. Kumar N, Bendall R, Legrand-Abravanel F, Xia NS, Ejaz S, et al. (2012) Hepatitis E. Lancet 379: 2457-2469.
5. Teo CG (2010) Much meat, much malady: changing perceptions of the epidemiology of hepatitis E. Clin Microbiol Infect 16: 24-32.
6. Colson P, Borentain P, Queyrain B, Kaha M, Moal V, et al. (2010) Pig liver sausage as a source of hepatitis E virus transmission to humans. J Infect Dis 202: 825-834.
7. Meng XJ, Wiseman B, Elvinger F, Guenette DK, Toth TE, et al. (2002) Prevalence of antibodies to hepatitis E virus in veterinarians working with swine and in normal blood donors in the United States and other countries. J Clin Microbiol 40: 117-122.
8. Kasomdorkbua C, Opriesnig T, Huang FF, Guenette DK, Thomas PJ, et al. (2005) Infectious swine hepatitis E virus is present in pig manure storage facilities on United States farms, but evidence of water contamination is lacking. Appl Environ Microbiol 71: 7831-7837.
9. La Rosa G, Pourshaban M, Iaconelli M, Vennarucci VS, Muscillo M (2010) Molecular detection of hepatitis E virus in sewage samples. Appl Environ Microbiol 76: 5870-5873.

Table 2. Cont.

| Risk factors | Level | Positives/Total (%) | Odds ratio (95% CI) | P value |
|--------------|-------|---------------------|---------------------|---------|
| Arthropods   | yes   | 1/4 (25.0%)         | 2.01 (0.21 to 19.50) | 0.55    |
|              | no    | 141/993 (14.2%)     |                     |         |
| Rabbit       | yes   | 4/22 (18.2%)        | 1.35 (0.45 to 4.04)  | 0.59    |
|              | no    | 138/975 (14.2%)     |                     |         |
| Dog          | yes   | 33/232 (14.2%)      | 1.00 (0.66 to 1.52)  | 1       |
|              | no    | 109/765 (14.3%)     |                     |         |
| Cat          | yes   | 31/300 (10.3%)      | 0.61 (0.40 to 0.93)  | 0.02    |
|              | no    | 111/697 (15.9%)     |                     |         |
| Rodent       | yes   | 3/18 (16.7%)        | 1.21 (0.35 to 4.23)  | 0.77    |
|              | no    | 139/979 (14.2%)     |                     |         |
| Horse        | yes   | 3/10 (30.0%)        | 2.62 (0.67 to 10.23) | 0.17    |
|              | no    | 139/987 (14.1%)     |                     |         |
| Reptile      | yes   | 0/19 (0%)           | n.a.                | 0.09    |
|              | no    | 142/978 (14.5%)     |                     |         |
| Bird         | yes   | 0/5 (0%)            | n.a.                | 1       |
|              | no    | 142/992 (14.3%)     |                     |         |

Abbreviations: CI, confidence interval; n.a., not applicable.

doi:10.1371/journal.pone.0087669.t002
10. McCreaey C, Martelli F, Grierson S, Ottanello F, Nevel A, et al. (2008) Excretion of hepatitis E virus by pigs of different ages and its presence in slurry stores in the United Kingdom. Vet Rec 163: 261–265.
11. Parashar D, Khalkar P, Arankalle VA (2011) Survival of hepatitis A and E viruses in soil samples. Clin Microbiol Infect 17: E1–4.
12. Meng XJ (2010) Hepatitis E virus: animal reservoirs and zoonotic risk. Vet Microbiol 140: 256–265.
13. Soid B, Ijaz S, Kafatos G, Booth L, Thomas HL, et al. (2009) Hepatitis E outbreak on cruise ship. Emerg Infect Dis 15: 1739–1744.
14. Stefanidis I, Zervou EK, Rizos C, Sygariani C, Patidou E, et al. (2004) Hepatitis E virus antibodies in hemodialysis patients: an epidemiological survey in central Greece. Int J Artif Organs 27: 842–847.
15. Mansuy JM, Bendall R, Legrand-Abravanel F, Saune K, Miedouge M, et al. (2011) Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis 17: 2309–2312.
16. Bryan JP, Iqbal M, Tsarev S, Malik IA, Duncan JF, et al. (2002) Epidemic of hepatitis E in a military unit in Abbottabad, Pakistan. Am J Trop Med Hyg 67: 662–668.
17. Clayson ET, Vaughn DW, Imms BL, Shrestha MP, Pandey R, et al. (1998) Association of hepatitis E virus with an outbreak of hepatitis at a military training camp in Nepal. J Med Virol 54: 178–182.
18. Eick A, Ticehurst J, Tobler S, Nevin R, Lindler L, et al. (2010) Hepatitis E seroprevalence and seroconversion among US military service members deployed to Afghanistan. J Infect Dis 202: 1302–1308.
19. Muys KS, Dharump P, Mammen MP, Siripraphana N, Rodkvamtook W, et al. (2007) Hepatitis E virus infection in Thai troops deployed with U.N. peacekeeping forces. Mil Med 172: 1217–1219.
20. Schnegg A, Burgisser P, Andre C, Kenfak-Foguena A, Canellini G, et al. (2013) An analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population. PLoS One 8: e62980.
21. Bendall R, Ellis V, Ijaz S, Ali R, Dalton H (2010) A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J Med Virol 82: 799–805.
22. Dalton HR, Stableforth W, Thurairajah P, Hazeldine S, Remmarace R, et al. (2008) Autochthonous hepatitis E in Southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, the elderly and patients with chronic liver disease. Eur J Gastroenterol Hepatol 20: 784–790.
23. Xu C, Wang RY, Schechterly CA, Ge S, Shih JW, et al. (2013) An assessment of hepatitis E virus (HEV) in US blood donors and recipients: no detectable HEV RNA in 1939 donors tested and no evidence for HEV transmission to 362 prospectively followed recipients. Transfusion 53 Suppl 3: 2505–2511.
24. Hofmann H, Holzmann H (1995) Incidence of hepatitis E in Austria. Wien Klin Wochenschr 107: 336–339.
25. Zentel D, Fink M, Revilla-Fernandez S, Steinrigl A, Winter P, et al. (2012) First detection of hepatitis E virus in Austrian pigs by RT-qPCR. Berl Munch Tierarztl Wochenschr 125: 281–289.
26. Christensen PB, Engle RE, Hijpt C, Homborg KM, Vach W, et al. (2008) Time trend of the prevalence of hepatitis E antibodies among farmers and blood donors: a potential zoonosis in Denmark. Clin Infect Dis 47: 1026–1031.
27. Kaufmann A, Kenfak-Foguena A, Andre C, Canellini G, Burgisser P, et al. (2011) Hepatitis E Virus Seroprevalence among Blood Donors in Southwest Switzerland. PLoS One 6: e21150.
28. Faber MS, Wenzel JJ, Jilg W, Thamm M, Hohle M, et al. (2012) Hepatitis E virus seroprevalence among adults, Germany. Emerg Infect Dis 18: 1654–1657.
29. Vernet M, Rossier-Lamourue M, Richet H, Roussin P, Pardo P, et al. (2013) Anti-hepatitis E virus antibody prevalence in French expatriate workers. Int J Infect Dis 17: e1082–4.
30. Teshale EH, Grytdal SP, Howard C, Barry V, Kamili S, et al. (2010) Evidence of person-to-person transmission of hepatitis E virus during a large outbreak in Northern Uganda. Clin Infect Dis 50: 1006–1010.
31. Guthmann JP, Kloostad H, Bocia D, Hamid N, Pinoges L, et al. (2006) A large outbreak of hepatitis E among a displaced population in Darfur, Sudan, 2004: the role of water treatment methods. Clin Infect Dis 42: 1685–1691.